HONG KONG HUALIAN HUATAI INDUSTRIAL GROUP CO., LIMITED – Trademark Portfolio
Entity Type: 77
HONG KONG HUALIAN HUATAI INDUSTRIAL GROUP CO., LIMITED holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include EASTIME and DR.YOUTH. The owner is based in HONG KONG.
ROOM 2, 13TH FLOOR, 55 WATERLOO ROAD
YAU MA TEI
HONG KONG , CN
Showing of trademarks Trademarks
Trademark Classifications
HONG KONG HUALIAN HUATAI INDUSTRIAL GROUP CO., LIMITED's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does HONG KONG HUALIAN HUATAI INDUSTRIAL GROUP CO., LIMITED have?
HONG KONG HUALIAN HUATAI INDUSTRIAL GROUP CO., LIMITED has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does HONG KONG HUALIAN HUATAI INDUSTRIAL GROUP CO., LIMITED file in?
HONG KONG HUALIAN HUATAI INDUSTRIAL GROUP CO., LIMITED files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are HONG KONG HUALIAN HUATAI INDUSTRIAL GROUP CO., LIMITED's most well-known trademarks?
HONG KONG HUALIAN HUATAI INDUSTRIAL GROUP CO., LIMITED's registered trademark portfolio includes well-known marks such as EASTIME and DR.YOUTH. These are among 2 currently registered trademarks in the portfolio.
What is HONG KONG HUALIAN HUATAI INDUSTRIAL GROUP CO., LIMITED's trademark registration success rate?
HONG KONG HUALIAN HUATAI INDUSTRIAL GROUP CO., LIMITED has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.